Revised forecast
Fiscal year ended February 2026 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Higher net sales resulting from steady business performance in the semiconductor, healthcare and new business segments; higher income due to the effect of higher net sales and improved efficiency of various costs; the absence of the extraordinary loss recorded in the previous fiscal year; and the recognition of a loss on the sale of shares and an adjustment to income taxes in the current fiscal year, among other factors.
In the previous fiscal year, extraordinary losses totaling ¥3,631 million were recorded, including a ¥3,261 million loss on the valuation of shares in consolidated subsidiary Raicol. In the current fiscal year, a ¥1,606 million loss on the sale of shares in the company was recorded.
| Item | Details |
|---|---|
| Net Sales | 1,673 |
| Operating profit | 786 |
| Ordinary income | 674 |
| Profit attributable to owners of the parent | 3,282 |
| Fiscal Period Covered | Fiscal year ended February 2026 |
| Period Covered | Full year |
| Previous-period results | Net sales: ¥6,920 million; operating income: ¥431 million; ordinary income: ¥403 million; net income: △¥3,271 million; net income per share: △¥295.18 |
| Reason for the revision | Higher net sales resulting from steady business performance in the semiconductor, healthcare and new business segments; higher income due to the effect of higher net sales and improved efficiency of various costs; the absence of the extraordinary loss recorded in the previous fiscal year; and the recognition of a loss on the sale of shares and an adjustment to income taxes in the current fiscal year, among other factors. |
| Details and amount of extraordinary loss | In the previous fiscal year, extraordinary losses totaling ¥3,631 million were recorded, including a ¥3,261 million loss on the valuation of shares in consolidated subsidiary Raicol. In the current fiscal year, a ¥1,606 million loss on the sale of shares in the company was recorded. |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business performed steadily in the semiconductor, healthcare and new business segments, resulting in higher net sales. In semiconductors, contributions came from growing demand for existing products and the launch of new products; in healthcare, from sales to new customers and shifts in shipping schedules; and in new businesses, from increased shipments of Faraday rotors against the backdrop of global demand for data centers. In addition to the effect of higher net sales, operating income and ordinary income increased as various costs were managed more efficiently. Net income increased due to the absence of the extraordinary loss recorded in the previous fiscal year, together with the recognition of a loss on the sale of shares and an adjustment to income taxes in the current fiscal year, among other factors.